Dolutegravir submitted to EU, US and Canadian regulatory agencies

1 February 2013. Related: Antiretrovirals.

On 17 December 2012, ViiV Healthcare issued a press release announcing the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572).

These submissions are for the treatment of HIV infection in adults and adolescents (children aged 12 years and older).

Reference:

ViiV press release. ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada. 17 December 2012.
http://www.viivhealthcare.com/media-room/press-releases/2012-12-17